Shared Inherited Genetics of Benign Prostatic Hyperplasia and Prostate Cancer

Berry, 1984, The development of human benign prostatic hyperplasia with age, J Urol, 132, 474, 10.1016/S0022-5347(17)49698-4 Siegel, 2021, Cancer statistics, 2021, CA Cancer J Clin, 71, 7, 10.3322/caac.21654 Roehrborn, 2008, Pathology of benign prostatic hyperplasia, Int J Impot Res, 20, S11, 10.1038/ijir.2008.55 McNeal, 1988, Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread, Am J Surg Pathol, 12, 897, 10.1097/00000478-198812000-00001 Alcaraz, 2009, Is there evidence of a relationship between benign prostatic hyperplasia and prostate cancer? Findings of a literature review, Eur Urol, 55, 864, 10.1016/j.eururo.2008.11.011 Orsted, 2013, The link between benign prostatic hyperplasia and prostate cancer, Nat Rev Urol, 10, 49, 10.1038/nrurol.2012.192 Sommers, 1957, Endocrine changes with prostatic carcinoma, Cancer, 10, 345, 10.1002/1097-0142(195703/04)10:2<345::AID-CNCR2820100215>3.0.CO;2-N Bostwick, 1992, The association of benign prostatic hyperplasia and cancer of the prostate, Cancer, 70, 291, 10.1002/1097-0142(19920701)70:1+<291::AID-CNCR2820701317>3.0.CO;2-4 Greenwald, 1974, Cancer of the prostate among men with benign prostatic hyperplasia, J Natl Cancer Inst, 53, 335, 10.1093/jnci/53.2.335 Armenian, 1974, Relation between benign prostatic hyperplasia and cancer of the prostate. A prospective and retrospective study, Lancet, 2, 115, 10.1016/S0140-6736(74)91551-7 Thompson, 1997, Chemoprevention of prostate cancer: the Prostate Cancer Prevention Trial, Prostate, 33, 217, 10.1002/(SICI)1097-0045(19971101)33:3<217::AID-PROS11>3.0.CO;2-N Andriole, 2010, Effect of dutasteride on the risk of prostate cancer, N Engl J Med, 362, 1192, 10.1056/NEJMoa0908127 Chokkalingam, 2003, Prostate carcinoma risk subsequent to diagnosis of benign prostatic hyperplasia: a population-based cohort study in Sweden, Cancer, 98, 1727, 10.1002/cncr.11710 Orsted, 2011, Association of clinical benign prostate hyperplasia with prostate cancer incidence and mortality revisited: a nationwide cohort study of 3,009,258 men, Eur Urol, 60, 691, 10.1016/j.eururo.2011.06.016 Zhang, 2020, Correlation between prostatitis, benign prostatic hyperplasia and prostate cancer: a systematic review and meta-analysis, J Cancer, 11, 177, 10.7150/jca.37235 National Cancer Institute. Understanding prostate changes: a health guide for men. https://www.cancer.gov/types/prostate/understanding-prostate-changes. Meigs, 1998, High rates of prostate-specific antigen testing in men with evidence of benign prostatic hyperplasia, Am J Med, 104, 517, 10.1016/S0002-9343(98)00113-2 Lerner, 2021, Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline part I—initial work-up and medical management, J Urol, 206, 806, 10.1097/JU.0000000000002183 Carroll, 2016, NCCN guidelines insights: prostate cancer early detection, version 2.2016, J Natl Compr Canc Netw, 14, 509, 10.6004/jnccn.2016.0060 Ni, 2018, Schizophrenia Working Group of the Psychiatric Genomics C, Wray NR, Lee SH. Estimation of genetic correlation via linkage disequilibrium score regression and genomic restricted maximum likelihood, Am J Hum Genet, 102, 1185, 10.1016/j.ajhg.2018.03.021 Conti, 2021, Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction, Nat Genet, 53, 65, 10.1038/s41588-020-00748-0 Gudmundsson, 2018, Genome-wide associations for benign prostatic hyperplasia reveal a genetic correlation with serum levels of PSA, Nat Commun, 9, 4568, 10.1038/s41467-018-06920-9 Bycroft, 2018, The UK Biobank resource with deep phenotyping and genomic data, Nature, 562, 203, 10.1038/s41586-018-0579-z Yu, 2019, Concept and benchmarks for assessing narrow-sense validity of genetic risk score values, Prostate, 79, 1099, 10.1002/pros.23821 Burgess, 2013, Mendelian randomization analysis with multiple genetic variants using summarized data, Genet Epidemiol, 37, 658, 10.1002/gepi.21758 Burgess, 2019, Guidelines for performing Mendelian randomization investigations, Wellcome Open Res, 4, 186, 10.12688/wellcomeopenres.15555.1 Flanigan, 1998, 5-Year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: a Department of Veterans Affairs cooperative study, J Urol, 160, 12, 10.1016/S0022-5347(01)63011-8 Izard, 2011, Impact of medical therapy on transurethral resection of the prostate: two decades of change, BJU Int, 108, 89, 10.1111/j.1464-410X.2010.09737.x Bulut, 2015, Effects of medical therapy or surgery on prostatic and bladder resistive indices in patients with benign prostatic hyperplasia, Urol Int, 94, 181, 10.1159/000363581 Krambeck, 2012, Effectiveness of medical and surgical therapies for lower urinary tract symptoms in the community setting, BJU Int, 110, 1332, 10.1111/j.1464-410X.2012.10998.x Shi, 2021, Performance of three inherited risk measures for predicting prostate cancer incidence and mortality: a population-based prospective analysis, Eur Urol, 79, 419, 10.1016/j.eururo.2020.11.014 Xu, 2008, Association of prostate cancer risk variants with clinicopathologic characteristics of the disease, Clin Cancer Res, 14, 5819, 10.1158/1078-0432.CCR-08-0934 Yamashiro, 2021, Any correlation between prostate volume and incidence of prostate cancer: a review of reported data for the last thirty years, Res Rep Urol, 13, 749